<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00246519</url>
  </required_header>
  <id_info>
    <org_study_id>U01GM074492</org_study_id>
    <nct_id>NCT00246519</nct_id>
  </id_info>
  <brief_title>Pharmacogenomic Evaluation of Antihypertensive Responses</brief_title>
  <official_title>Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are many medications available for the treatment of high blood pressure (hypertension),
      but finding the right one for a specific patient can be challenging. In fact, it is estimated
      that only 34% of people with hypertension have their blood pressure under control. The
      hypothesis is that genetic differences between individuals influence their response to
      antihypertensive medications. This study is aimed at determining the genetic factors that may
      influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is
      that through this research, we may someday be able to use an individual's genetic information
      to guide the selection of their blood pressure medicine, leading to better control of blood
      pressure, and less need for the current trial and error process.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed work should help move toward the long-term goal of selection of antihypertensive
      drug therapy based on a patient's genetic make-up. Hypertension (HTN) is the most common
      chronic disease for which drugs are prescribed, and the most prevalent risk factor for heart
      attack, stroke, renal failure and heart failure. Responses to antihypertensive drug therapy
      exhibit considerable interpatient variability, contributing to poor rates of HTN control
      (currently 34% in the US), and frequent nonadherence and dropout from therapy. We propose to
      identify genetic predictors of the antihypertensive and adverse metabolic responses to two
      preferred and pharmacodynamically contrasting drugs, a beta-blocker (atenolol) and a thiazide
      diuretic (hydrochlorothiazide) given initially as monotherapy, and subsequently in
      combination, to 800 individuals with uncomplicated hypertension. High quality phenotype data,
      including both home and ambulatory measures of blood pressure (BP) response, and lipid and
      insulin sensitivity measures of adverse metabolic responses will be related to genetic
      variation through two approaches. First, testing 7 single nucleotide polymorphisms (SNPs) in
      each of 70 candidate genes, we will examine the influence of these genes' variation on
      responses to beta-blockers and diuretics (Specific Aim 1). This will include assessment of
      genetic associations with: antihypertensive responses to monotherapy (Aim 1a), addition of a
      second drug to monotherapy (Aim 1b), and combination therapy (Aim 1c); and adverse metabolic
      responses to mono and combination therapy (Aim 1d). This candidate gene approach will be
      supplemented by discovery of novel genes involved in variable BP and metabolic responses to
      beta-blockers and diuretics through testing of 20,000 putative functional SNPs that span the
      human genome (Specific Aim 2). As in Aim 1, Aim 2 will include testing for associations with
      antihypertensive and adverse metabolic responses to monotherapy and combination therapy. The
      proposed research will substantially increase our understanding of the pharmacogenetics of
      mono- and combination antihypertensive drug therapy. It will also lead to creation of data
      sets and samples that can be used by others in the field, through deposit of data to
      PharmGKB, and creation of immortalized cell lines from all study participants to share data
      and biological samples with other researchers. The proposed research is significant because
      genetically-targeted antihypertensive therapy could lead to dramatically higher response
      rates and fewer adverse effects than the usual trial-and-error approach. This would likely
      lead to higher rates of HTN control, less need for polypharmacy, reduced health care costs,
      and improved outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)).</measure>
    <time_frame>baseline to 18 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Metabolic Responses</measure>
    <time_frame>9-18 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1701</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atenolol 50 mg, then 100 mg if BP &lt; 120/70, then add HCTZ 12.5 mg if BP &lt; 120/70, then HCTZ 25 mg if BP &lt; 120/70</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide (HCTZ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCTZ 12.5 mg then HCTZ 25 mg if BP &lt; 120/70, then add atenolol 50 mg if BP &lt; 120/70, then atenolol 100 mg if BP &lt; 120/70.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg</description>
    <arm_group_label>Hydrochlorothiazide (HCTZ)</arm_group_label>
    <other_name>Aquazide H or HydroDIURIL or Microzide</other_name>
    <other_name>Lopressor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>atenolol 50 mg, then 100 mg if BP &lt; 120/70, then add HCTZ 12.5 mg if BP &lt; 120/70, then HCTZ 25 mg if BP &lt; 120/70</description>
    <arm_group_label>Atenolol</arm_group_label>
    <other_name>Lopressor</other_name>
    <other_name>Aquazide H or HydroDIURIL or Microzide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        An average seated home diastolic blood pressure (DBP) &gt; 85 mmHg and home systolic blood
        pressure (SBP) &lt; 180 mmHg. Subjects must also have an average seated (&gt; 5 minutes) clinic
        DBP between 90 mmHg and 110 mmHg and SBP &lt; 180 mmHg

        Exclusion Criteria:

        secondary forms of HTN, patients currently treated with three or more antihypertensive
        drugs, isolated systolic HTN, other diseases requiring treatment with BP lowering
        medications, heart rate &lt; 55 beats/min, known cardiovascular disease (including history of
        angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial
        infarction or revascularization procedure, or cerebrovascular disease, including stroke and
        TIA), diabetes mellitus (Type 1 or 2), renal insufficiency (serum creatinine &gt; 1.5 in men
        or 1.4 in women), primary renal disease, pregnancy or lactation, liver enzymes &gt; 2.5 upper
        limits of normal, current treatment with NSAIDS, cyclooxygenase-2 (COX2) inhibitors, oral
        contraceptives or estrogen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie A Johnson, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Department of Community Health and Family Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pear.cop.ufl.edu/</url>
    <description>PEAR website</description>
  </link>
  <results_reference>
    <citation>Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-DeHoff RM, Gums J, Curry RW, Gong Y, Beitelshees AL, Schwartz G, Turner ST. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J. 2009 Mar;157(3):442-9. doi: 10.1016/j.ahj.2008.11.018.</citation>
    <PMID>19249413</PMID>
  </results_reference>
  <results_reference>
    <citation>Johnson JA, Gong Y, Bailey KR, Cooper-DeHoff RM, Chapman AB, Turner ST, Schwartz GL, Campbell K, Schmidt S, Beitelshees AL, Boerwinkle E, Gums JG. Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order. Clin Pharmacol Ther. 2009 Nov;86(5):533-9. doi: 10.1038/clpt.2009.101. Epub 2009 Jul 1.</citation>
    <PMID>19571804</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, Cooper-Dehoff RM, Schwartz GL, Bailey K, Chapman A, Hall KL, Feng H, Boerwinkle E, Johnson JA, Gums JG. Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy. 2009 Oct;29(10):1157-65. doi: 10.1592/phco.29.10.1157.</citation>
    <PMID>19792989</PMID>
  </results_reference>
  <results_reference>
    <citation>Cooper-DeHoff RM, Wen S, Beitelshees AL, Zineh I, Gums JG, Turner ST, Gong Y, Hall K, Parekh V, Chapman AB, Boerwinkle E, Johnson JA. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010 Jan;55(1):61-8. doi: 10.1161/HYPERTENSIONAHA.109.139592. Epub 2009 Nov 16.</citation>
    <PMID>19917874</PMID>
  </results_reference>
  <results_reference>
    <citation>Beitelshees AL, Gong Y, Bailey KR, Turner ST, Chapman AB, Schwartz GL, Gums JG, Boerwinkle E, Johnson JA. Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide. J Clin Hypertens (Greenwich). 2010 Jan;12(1):14-21. doi: 10.1111/j.1751-7176.2009.00185.x. Erratum in: J Clin Hypertens (Greenwich). 2010 Mar 1;12(3):192.</citation>
    <PMID>20047624</PMID>
  </results_reference>
  <results_reference>
    <citation>Duarte JD, Lobmeyer MT, Wang Z, Chapman AB, Gums JG, Langaee TY, Boerwinkle E, Turner ST, Johnson JA. Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. Pharmacogenet Genomics. 2010 Aug;20(8):516-9. doi: 10.1097/FPC.0b013e32833b5958.</citation>
    <PMID>20555294</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith SM, Gong Y, Turner ST, Cooper-DeHoff RM, Beitelshees AL, Chapman AB, Boerwinkle E, Bailey K, Johnson JA, Gums JG. Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. Am J Hypertens. 2012 Mar;25(3):359-65. doi: 10.1038/ajh.2011.215. Epub 2011 Nov 17.</citation>
    <PMID>22089105</PMID>
  </results_reference>
  <results_reference>
    <citation>Lobmeyer MT, Wang L, Zineh I, Turner ST, Gums JG, Chapman AB, Cooper-DeHoff RM, Beitelshees AL, Bailey KR, Boerwinkle E, Pepine CJ, Johnson JA. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics. 2011 Jan;21(1):42-9. doi: 10.1097/FPC.0b013e328341e911.</citation>
    <PMID>21127457</PMID>
  </results_reference>
  <results_reference>
    <citation>Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010 Jul 7;304(1):61-8. doi: 10.1001/jama.2010.884.</citation>
    <PMID>20606150</PMID>
  </results_reference>
  <results_reference>
    <citation>Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens. 2010 Sep;23(9):1014-22. doi: 10.1038/ajh.2010.98. Epub 2010 Aug 19.</citation>
    <PMID>20725057</PMID>
  </results_reference>
  <results_reference>
    <citation>Wikoff WR, Frye RF, Zhu H, Gong Y, Boyle S, Churchill E, Cooper-Dehoff RM, Beitelshees AL, Chapman AB, Fiehn O, Johnson JA, Kaddurah-Daouk R; Pharmacometabolomics Research Network. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One. 2013;8(3):e57639. doi: 10.1371/journal.pone.0057639. Epub 2013 Mar 11.</citation>
    <PMID>23536766</PMID>
  </results_reference>
  <results_reference>
    <citation>Del-Aguila JL, Beitelshees AL, Cooper-Dehoff RM, Chapman AB, Gums JG, Bailey K, Gong Y, Turner ST, Johnson JA, Boerwinkle E. Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. Pharmacogenomics J. 2014 Feb;14(1):35-40. doi: 10.1038/tpj.2013.3. Epub 2013 Feb 12.</citation>
    <PMID>23400010</PMID>
  </results_reference>
  <results_reference>
    <citation>McDonough CW, Burbage SE, Duarte JD, Gong Y, Langaee TY, Turner ST, Gums JG, Chapman AB, Bailey KR, Beitelshees AL, Boerwinkle E, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens. 2013 Apr;31(4):698-704. doi: 10.1097/HJH.0b013e32835e2a71.</citation>
    <PMID>23353631</PMID>
  </results_reference>
  <results_reference>
    <citation>Gong Y, McDonough CW, Wang Z, Hou W, Cooper-DeHoff RM, Langaee TY, Beitelshees AL, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Turner ST, Johnson JA. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet. 2012 Dec;5(6):686-91. doi: 10.1161/CIRCGENETICS.112.964080. Epub 2012 Oct 19.</citation>
    <PMID>23087401</PMID>
  </results_reference>
  <results_reference>
    <citation>Vandell AG, Lobmeyer MT, Gawronski BE, Langaee TY, Gong Y, Gums JG, Beitelshees AL, Turner ST, Chapman AB, Cooper-DeHoff RM, Bailey KR, Boerwinkle E, Pepine CJ, Liggett SB, Johnson JA. G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012 Oct;60(4):957-64. doi: 10.1161/HYPERTENSIONAHA.112.198721. Epub 2012 Sep 4.</citation>
    <PMID>22949529</PMID>
  </results_reference>
  <results_reference>
    <citation>Duarte JD, Zineh I, Burkley B, Gong Y, Langaee TY, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Cooper-Dehoff RM, Beitelshees AL, Bailey KR, Fillingim RB, Kone BC, Johnson JA. Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. J Transl Med. 2012 Mar 22;10:56. doi: 10.1186/1479-5876-10-56.</citation>
    <PMID>22440088</PMID>
  </results_reference>
  <results_reference>
    <citation>Duarte JD, Turner ST, Tran B, Chapman AB, Bailey KR, Gong Y, Gums JG, Langaee TY, Beitelshees AL, Cooper-Dehoff RM, Boerwinkle E, Johnson JA. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. Pharmacogenomics J. 2013 Jun;13(3):257-63. doi: 10.1038/tpj.2012.4. Epub 2012 Feb 21.</citation>
    <PMID>22350108</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2005</study_first_submitted>
  <study_first_submitted_qc>October 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2005</study_first_posted>
  <results_first_submitted>May 20, 2013</results_first_submitted>
  <results_first_submitted_qc>July 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 10, 2013</results_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>pharmacogenetics</keyword>
  <keyword>pharmacogenomics</keyword>
  <keyword>beta-blocker</keyword>
  <keyword>atenolol</keyword>
  <keyword>diuretic</keyword>
  <keyword>hydrochlorothiazide</keyword>
  <keyword>blood pressure</keyword>
  <keyword>metabolic adverse effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Trichlormethiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited to 3 sites, the University of Florida, Mayo Clinic in Rochester Minnesota, and Emory University. Subjects were seen in medical clinics by physicians and/or nurse coordinators. Patients were recruited from 2005-2010.</recruitment_details>
      <pre_assignment_details>After enrollment subjects were currently on medication for blood pressure were required to wash out for a minimum of 2-4 weeks, at which point the blood pressure was reassessed for eligibility into the study. Of the 1701 subjects who enrolled in the study, 888 subjects met eligibility requirements to continue the study while 813 subjects did not.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atenolol + Hydroclorothiazide (HCTZ) Arm</title>
          <description>atenolol 50 mg, then 100 mg if BP &lt; 120/70, then add HCTZ 12.5 mg if BP &lt; 120/70, then HCTZ 25 mg if BP &lt; 120/70</description>
        </group>
        <group group_id="P2">
          <title>Hydrochlorothiazide (HCTZ) + Atenolol</title>
          <description>HCTZ 12.5 mg then HCTZ 25 mg if BP &lt; 120/70, then add atenolol 50 mg if BP &lt; 120/70, then atenolol 100 mg if BP &lt; 120/70.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="442"/>
                <participants group_id="P2" count="446"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="386"/>
                <participants group_id="P2" count="382"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atenolol +HCTZ Arm</title>
          <description>atenolol 50 mg, then 100 mg if BP &lt; 120/70, then add HCTZ 12.5 mg if BP &lt; 120/70, then HCTZ 25 mg if BP &lt; 120/70</description>
        </group>
        <group group_id="B2">
          <title>HCTZ + Atenolol</title>
          <description>HCTZ 12.5 mg then HCTZ 25 mg if BP &lt; 120/70, then add atenolol 50 mg if BP &lt; 120/70, then atenolol 100 mg if BP &lt; 120/70.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="442"/>
            <count group_id="B2" value="446"/>
            <count group_id="B3" value="888"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="437"/>
                    <measurement group_id="B2" value="440"/>
                    <measurement group_id="B3" value="877"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.4" spread="9.3"/>
                    <measurement group_id="B2" value="48.8" spread="9.2"/>
                    <measurement group_id="B3" value="48.6" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="474"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="442"/>
                    <measurement group_id="B2" value="446"/>
                    <measurement group_id="B3" value="888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)).</title>
        <time_frame>baseline to 18 weeks of treatment</time_frame>
        <population>A total 768 patients had at least monotherapy response data. Of the 386 patients assigned to the atenolol arm, 357 completed both drugs. Of the 382 assigned to the HCTZ arm, 355 completed both drugs. The delta blood pressure below is for patients who completed both drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol +HCTZ Arm</title>
            <description>atenolol 50 mg, then 100 mg if BP &lt; 120/70, then add HCTZ 12.5 mg if BP &lt; 120/70, then HCTZ 25 mg if BP &lt; 120/70</description>
          </group>
          <group group_id="O2">
            <title>HCTZ + Atenolol</title>
            <description>HCTZ 12.5 mg then HCTZ 25 mg if BP &lt; 120/70, then add atenolol 50 mg if BP &lt; 120/70, then atenolol 100 mg if BP &lt; 120/70.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)).</title>
          <population>A total 768 patients had at least monotherapy response data. Of the 386 patients assigned to the atenolol arm, 357 completed both drugs. Of the 382 assigned to the HCTZ arm, 355 completed both drugs. The delta blood pressure below is for patients who completed both drugs.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
                <count group_id="O2" value="355"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.06" spread="6.96"/>
                    <measurement group_id="O2" value="-13.33" spread="6.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Metabolic Responses</title>
        <time_frame>9-18 weeks of treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atenolol +HCTZ Arm</title>
          <description>atenolol 50 mg, then 100 mg if BP &lt; 120/70, then add HCTZ 12.5 mg if BP &lt; 120/70, then HCTZ 25 mg if BP &lt; 120/70</description>
        </group>
        <group group_id="E2">
          <title>HCTZ + Atenolol</title>
          <description>HCTZ 12.5 mg then HCTZ 25 mg if BP &lt; 120/70, then add atenolol 50 mg if BP &lt; 120/70, then atenolol 100 mg if BP &lt; 120/70.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inflamed colon or colonitis</sub_title>
                <description>1 had inflamed colon; 1 had colon colitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="386"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="386"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="386"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="386"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tiredness/Fatigue</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="386"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="386"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="386"/>
                <counts group_id="E2" events="38" subjects_affected="35" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="123" subjects_affected="123" subjects_at_risk="386"/>
                <counts group_id="E2" events="99" subjects_affected="98" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="386"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="382"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="386"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="386"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="382"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial has limited number of hypertensive patients of African ancestry, therefore power is limited to those patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Julie A. Johnson</name_or_title>
      <organization>University of Florida</organization>
      <phone>352-273-6007</phone>
      <email>johnson@cop.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

